How to Plead a Patent Infringement Action in Canada, Federal Court Step‑by‑step (2026 Update)

Knowing how to plead patent infringement in Canada is the single most consequential procedural decision a patent owner or exclusive licensee faces when an infringing product or process surfaces on the Canadian market. The Federal Court of Canada is the primary forum for these disputes, offering Canada-wide remedies, specialist judicial expertise and exclusive jurisdiction over certain patent matters under the Patent Act (R. S. C. , 1985, c. P‑4) and the Federal Courts Act. This guide sets out the complete patent pleadings procedure, from pre-action prerequisites through originating documents, discovery steps, interim remedies and trial preparation, with the documents, timelines and costs that in‑house counsel, pharmaceutical and biotech legal teams need in 2026.

Readers should note that ongoing procedural reforms are tightening disclosure windows and sharpening scrutiny of claim construction, making early and precise drafting more important than ever.

Overview of the Process and Who It Applies To

Patent infringement proceedings in Canada may be brought in either the Federal Court or a provincial superior court. In practice, the vast majority of patent actions, particularly those involving pharmaceutical, biotech and technology patents, are commenced in the Federal Court. The court has jurisdiction to resolve disputes regarding intellectual property rights, including patent infringement, patent validity, and matters arising under the Patented Medicines (Notice of Compliance) Regulations (PM(NOC)).

Federal Court pleadings carry several structural advantages for patent owners. Orders of the Federal Court are enforceable across Canada without the need for provincial registration. The court maintains a bench of judges experienced in patent matters and has well-developed case-management procedures for complex IP litigation. For pharmaceutical patent holders, the Federal Court is the only forum for PM(NOC) proceedings, an increasingly critical pathway as generic drug and biosimilar filings accelerate.

Typical relief available in a Federal Court patent infringement action includes:

• Permanent and interlocutory injunctions restraining the manufacture, use, sale or importation of infringing products.
• Damages or an accounting of profits at the election of the successful plaintiff.
• Delivery up or destruction of infringing goods, moulds, tooling and related materials.
• Declarations of infringement and validity.
• Reasonable compensation for pre-grant infringement under section 55 of the Patent Act.

Provincial superior courts retain concurrent jurisdiction over patent infringement claims under section 20 of the Federal Courts Act. Industry observers note, however, that provincial courts are typically chosen only when the dispute is geographically confined, or where a related contract or tort claim makes a single provincial proceeding more efficient.

Eligibility and Prerequisites for Commencing a Patent Infringement Claim

Before preparing Federal Court pleadings, counsel must verify that the foundational requirements for standing, territorial jurisdiction and, where applicable, regulatory triggers are met.

Who May Sue

Under the Patent Act, a patent infringement action may be commenced by the patentee of record or by any person claiming under the patentee, most commonly an exclusive licensee with express authority to sue. Joint patentees generally must act together unless the co-ownership agreement provides otherwise. Foreign patent owners may bring actions in the Federal Court provided the patent is a granted Canadian patent and the alleged infringing acts occur within Canada.

Territorial Requirement

To infringe a Canadian patent, the infringing activity, making, constructing, using or selling the patented invention, must take place in Canada. The Canadian Intellectual Property Office (CIPO) confirms that all essential elements of a patent claim must be present in the accused product or process to establish infringement. Offering to sell or importing an infringing article into Canada may also constitute infringement, even where manufacture occurs abroad.

PM(NOC) Notice of Allegation, The 45‑Day Trigger

In pharmaceutical patent litigation, the Patented Medicines (Notice of Compliance) Regulations (SOR/93‑133) create a distinct procedural trigger. When a generic manufacturer or biosimilar applicant serves a Notice of Allegation (NOA) on the innovator, the innovator may commence an action in the Federal Court within 45 days of receiving the NOA. If the action is commenced within that window, a statutory stay can prevent Health Canada from issuing a Notice of Compliance to the generic applicant for up to 24 months. Missing the 45‑day NOA deadline forfeits the right to the stay, a potentially outcome-determinative consequence in the pharma sector.

Pre-Action Steps

While not legally required, sending a demand letter before filing is standard practice. A well-drafted demand letter puts the defendant on notice, may establish the date from which wilful infringement is assessed, and can facilitate early settlement. Counsel should ensure that demand correspondence does not contain admissions that could narrow the scope of subsequent pleadings. Evidence preservation, including retaining samples of the accused product, capturing online listings, and securing internal testing data, should begin immediately once infringement is suspected.

How to Plead Patent Infringement in Canada, Step‑by‑Step Federal Court Procedure

The following numbered steps map the patent pleadings procedure from the originating document through case management. The timeline table at the end of this section summarises who does what and typical durations.

Step 1: Prepare and File the Originating Document

A patent infringement action in the Federal Court is commenced by filing a Statement of Claim in the form prescribed by the Federal Court’s official forms. The Statement of Claim is the originating document and must be drafted to meet the material-facts pleading standard set out in the Federal Courts Rules (SOR/98‑106).

The plaintiff must set out specific infringing facts, not merely conclusions of law. Federal Court jurisprudence consistently holds that a patent infringement pleading must include:

• The patent number, grant date and title, with identification of the specific claims alleged to be infringed.
• A description of the defendant’s infringing acts, including dates, places and, where known, quantities, sufficient to allow the defendant to understand the case it must meet.
• A claim chart or infringement map correlating each asserted claim element to the corresponding feature of the accused product or process. In biotech and pharmaceutical cases, this typically includes mechanism of action, formulation details or ANDS reference product specifications.
• The relief sought: injunction, damages or accounting of profits, delivery up, and any other specific orders.

Failure to plead sufficient particulars can result in the pleading being struck or the plaintiff being ordered to provide further and better particulars, an outcome that delays the proceeding and signals weakness to the opposing party. The Federal Court has repeatedly emphasised that boilerplate infringement allegations, without identifying specific acts and claim elements, are insufficient.

For proceedings involving confidential technical information, counsel should consider attaching technical schedules under a proposed protective order or confidentiality ring arrangement from the outset, rather than omitting critical detail from the pleading.

Step 2: File, E‑File and Serve the Statement of Claim

The Statement of Claim is filed with the Federal Court registry, which now strongly encourages electronic filing through the court’s e‑filing portal. Filing generates a court file number. The plaintiff must then serve the originating document on each defendant. Service may be effected personally, by an alternative to personal service permitted under the Federal Courts Rules, or, with leave, by substitutional service where the defendant cannot be located.

After service, a proof-of-service affidavit is filed with the court. The defendant then has a prescribed period, typically 30 days if served in Canada, within which to file and serve a Statement of Defence. If the defendant is served outside Canada, extended timelines apply under the Rules.

Where urgency demands it, a plaintiff may bring an ex parte motion for an interim injunction or a preservation order immediately upon filing, before the defendant has been served. This pathway is reserved for cases where delay would cause irreparable harm, for example, where infringing goods are about to be shipped or destroyed.

Step 3: Defendant’s Response and Pleading of Defences or Counterclaims

The defendant’s Statement of Defence must respond to each allegation in the Statement of Claim and plead all material facts supporting its defence. Common defences in patent infringement proceedings include:

• Non-infringement: The accused product or process does not practise each essential element of the asserted claims.
• Invalidity: The patent is invalid on one or more grounds, anticipation, obviousness, insufficiency of disclosure, overbreadth, or lack of utility. Invalidity allegations must be pleaded with particulars, including identification of specific prior art references with dates and sources.
• Abuse of patent rights, exhaustion or implied licence.

Defendants frequently file a counterclaim for a declaration of invalidity, which the plaintiff must then answer. The counterclaim may also seek a declaration of non-infringement. Once pleadings close, typically when all statements of defence, counterclaims and replies have been exchanged, the matter proceeds to case management and discovery.

Step 4: Disclosure, Discovery and Expert Evidence

Following the close of pleadings, each party must produce an Affidavit of Documents listing all relevant documents in its possession, control or power. In patent cases, plaintiff disclosure typically includes the patent file wrapper (prosecution history), internal testing data, sales records, technical drawings and prior art considered during prosecution. Defendants must disclose their own product specifications, manufacturing processes, development records and any prior art on which they rely for invalidity.

Examinations for discovery, oral cross-examinations of a representative of each party, follow document production. Discovery in patent cases is often technically intensive and may require the examining counsel to retain scientific advisors to formulate questions.

Expert evidence is central to patent litigation. Experts are typically retained to address:

• Claim construction: Interpreting the meaning and scope of the patent claims through the eyes of the skilled person.
• Infringement analysis: Comparing the accused product or process against each claim element.
• Validity opinions: Assessing whether the patent meets the statutory requirements of novelty, non-obviousness and utility.

Expert reports are exchanged on a schedule directed by the case management judge, commonly 90 to 180 days before trial. Early retention of qualified experts is critical: in biotech and pharmaceutical disputes, the pool of available experts with the requisite specialisation is limited, and 2026 practice trends favour tighter expert-evidence schedules.

Confidentiality is a perennial concern. Protective orders and confidentiality rings, which restrict access to commercially sensitive documents to outside counsel and independent experts, are standard in pharmaceutical patent litigation. Draft protective order templates should be prepared at the outset and negotiated promptly with opposing counsel.

Step 5: Interim Remedies, Motions and Case Management to Trial

At any point after filing, the plaintiff may move for interlocutory relief. The test for an interlocutory injunction in patent cases follows the established three-part framework: the plaintiff must demonstrate a serious question to be tried (prima facie case), that it will suffer irreparable harm if the injunction is refused, and that the balance of convenience favours granting the order.

Other interim remedies include:

• Preservation orders (Anton Piller): Permitting inspection and seizure of evidence at the defendant’s premises, granted ex parte where there is a real risk of destruction.
• Mareva injunctions: Freezing the defendant’s assets where dissipation is apprehended.
• Norwich orders: Compelling third parties (such as customs brokers or distributors) to disclose the identity of alleged infringers.

Case management conferences are typically ordered early in the proceeding. The case management judge sets a timetable governing all remaining steps, including amendments to pleadings, completion of discovery, delivery of expert reports and the trial date. Adhering to case-management deadlines is essential; the Federal Court takes a dim view of delay and may impose costs consequences for non-compliance.

Settlement discussions and alternative dispute resolution, including mediation, may be directed or encouraged by the case management judge. In PM(NOC) cases, the statutory stay mechanism may itself create settlement incentives, as the stay effectively blocks the generic product from market entry pending resolution.

Required Documents and Information, Patent Infringement Pleadings Checklist

Assembling the right documents before drafting the Statement of Claim reduces the risk of deficient particulars and accelerates the proceeding. The following checklist covers the documents needed for a Federal Court patent infringement action.

Timeline and Key Deadlines for Patent Infringement Pleadings

Strict compliance with the patent pleadings procedure timeline is essential. Missing a statutory or court-ordered deadline can result in dismissal, loss of the PM(NOC) stay, or adverse cost awards. The table below summarises the key deadlines governing a Federal Court patent infringement action.

Costs, Fees and Budgeting Considerations

The costs of a patent action in Federal Court can vary enormously depending on the technology area, the number of patents and claims at issue, and the scope of discovery. The following table provides indicative guidance on major cost categories. All filing fee amounts should be confirmed against the current Federal Court fee schedule before filing.

Budgeting should account for the possibility of a counterclaim for invalidity, which effectively doubles the discovery and expert evidence burden. In pharmaceutical cases, the statutory stay under the PM(NOC) Regulations adds a further cost-benefit dimension: the commercial value of maintaining market exclusivity during the stay period often justifies significant litigation expenditure.

What Changed in 2026, Procedural Reforms Affecting Patent Pleadings

Several developments in 2026 are reshaping how patent infringement actions are pleaded and managed in the Federal Court. Industry observers expect these trends to intensify through 2027 and beyond.

• Heightened scrutiny of claim construction in pleadings. The Federal Court is increasingly requiring parties to articulate their claim construction positions earlier in the proceeding. The likely practical effect is that plaintiffs must include more detailed claim interpretation arguments in their originating pleadings, rather than deferring construction issues to expert evidence at trial.
• Tighter disclosure and expert evidence windows. Case management judges are compressing the timetable for document production and expert report delivery. Early indications suggest that parties who fail to identify key prior art and retain experts promptly face adverse scheduling consequences.
• Emphasis on focused claim charts. Evolving practice directions encourage concise, element-by-element claim charts attached to the Statement of Claim. Overly broad or boilerplate infringement allegations are being struck with greater frequency, reinforcing the need for precise pleading from the outset.

Common Pitfalls and How to Avoid Them

• Insufficient particulars. Pleading infringement in general terms without identifying specific acts, dates and claim elements invites a motion to strike. Always prepare and attach a detailed claim chart.
• Over-broad or boilerplate pleadings. Asserting every claim of the patent without analysis weakens the case and increases costs. Focus on the strongest independent claims and their dependents.
• Late expert retention. In niche biotech fields, qualified experts are scarce. Engage experts before filing where possible to ensure the claim chart and particulars are technically sound.
• Poor evidence preservation. Failing to preserve product samples, online listings or internal communications before they are altered or deleted can be fatal to the infringement case.
• E-filing and service defects. Non-compliance with Federal Court e-filing requirements or improper service may invalidate the proceeding. Verify compliance with the Federal Courts Rules and the court’s practice directions on electronic filing.

Sources

1. Federal Court of Canada, Intellectual Property Jurisdiction
2. Federal Court of Canada, Forms
3. Federal Courts Rules (SOR/98‑106), Justice Laws Website
4. Patent Act (R.S.C., 1985, c. P‑4), Justice Laws Website
5. Canadian Intellectual Property Office (CIPO), Patent Theft
6. Canadian Intellectual Property Office (CIPO), Settling IP Disputes in Court
7. Patented Medicines (Notice of Compliance) Regulations (SOR/93‑133), Justice Laws Website
8. CanLII, Canadian Legal Information Institute